Skip to content
Menu
November 17, 2021
OWP Pharmaceuticals Announces IND Authorization for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder
Share this press release:
Document loads below this notification.
×
Dismiss alert
Prev
Previous PR
Next PR
Next
Additional Press Releases
November 30, 2022
/
Press Release
OWP Pharmaceuticals Announces Patent Application for First Oral Liquid Formulation of Trazodone for Treatment of MDD
January 5, 2022
/
Press Release
OWP Pharmaceuticals and EVERSANA Announce Partnership to Commercialize Oral Liquid Formulations to Treat Neuroscience Disorders
July 1, 2021
/
Press Release
OWP Pharmaceuticals Announces Patent Issuance for the First-Ever Oral Liquid Suspension of Quetiapine for the Treatment of Schizophrenia and Bipolar Disorder
View All Press Releases
View All Press Releases
CloseMenu
About Us
Our Purpose
Our People
Leadership Team
Board of Directors
FAQs
Products
Subvenite Starter Kits
Lamotrigine Starter Kits
Roweepra IR
Our Future
Pipeline
News
Press Releases
Events
Connect
Careers
Contact Us
© 2023 OWP Pharmaceuticals, Inc., All Rights Reserved.
Social Media Policy
|
Terms of Use
© 2023 OWP Pharmaceuticals, Inc., All Rights Reserved.
Social Media Policy
|
Terms of Use
© 2023 OWP Pharmaceuticals, Inc., All Rights Reserved.
Social Media Policy
|
Terms of Use
